Pemphigus is an autoimmune blistering disease, through this hospital series, we aim to describe our clinic-therapeutic experience in pemphigus. We performed a unicentric retrospective study of all patients admitted to the university hospital Ibn Sina Rabat Morocco with the diagnosis of pemphigus from 1990 to 2020 (over 30 years). Inclusion criteria; age, gender, mean duration of the disease, mortality rate, treatment, disease course. The diagnosis was mainly clinical and confirmed by histopathology, direct immunofluorescence and indirect immunofluorescence. There were 302 cases, 26 new patients in 2020. The most common variant was pemphigus vulgaris 125 cases followed by pemphigus seborrheic 99 cases, foliaceous 40 and vegetans 27 cases. sex-ratio 0.75, the average age; 53 years old, the mean duration of the disease before diagnosis was 13, 36 months, severe PDAI76%. Oral corticosteroids therapy prednisone was given to 133 cases, methylprednisolone to 12 cases. Adjuvants therapy with azathioprine (93 cases), disulone (22 cases), cyclophosphamide (1 case), methotrexate (2 cases), rituximab (9 cases), azathioprine and methotrexate (3 cases), azathioprine and rituximab (3 cases). Clinical remission (133 cases) (meanduration 2.5 months), lost to follow-up (39 cases); relapses (89 cases) (meanduration 51 months), death (33 cases). In our series, no statistical differences have been noted concerning the duration of the remission between oral steroids only and the association with a immunosuppressive agent. For economical reasons azathioprine is the most used sparing agent. The duration of treatment is very prolonged, we suggest a progressive tapering of steroids. Our recommendations to discontinue treatment in a patient with clinical remission on low doses of oral steroids is the absence of new lesions and circulating antibodies. Usually over than 2 years with a close monitoring of drugs side effects.